Primary Sclerosing Cholangitis: Why Liver Transplant May Be the Only Cure, the IBD Connection, and Cancer Surveillance

Research-informed explainer — last updated April 12, 2026

Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease that scars and narrows the bile ducts — and no drug has ever been shown to slow its progression, meaning liver transplantation remains the only cure for patients who reach end-stage disease. What makes PSC especially challenging is its strong association with inflammatory bowel disease, a lifetime risk of bile duct cancer, and the absence of reliable early warning signs until serious complications develop.

This article draws on research from five specialists. Anthony Kalloo, MD, Professor of Medicine at Johns Hopkins and Chair of Medicine at Maimonides Medical Center, contributed to the major American Association for the Study of Liver Diseases (AASLD) guideline on PSC diagnosis and management (1,214 citations), which remains the clinical reference for workup and treatment decisions. Christopher Bowlus, MD, Lena Valente Professor and Chief of Gastroenterology and Hepatology at UC Davis, is lead author on the 2022 AASLD practice guidance on PSC and cholangiocarcinoma (303 citations), co-authored a genome-wide study identifying nine new PSC risk loci (393 citations), and contributed to clinical trials of the FXR agonist cilofexor (251 citations). Cynthia Levy, MD, Associate Director of the Schiff Center for Liver Diseases at the University of Miami, published the landmark study on CA 19-9 as a predictor of cholangiocarcinoma in PSC patients (335 citations) and contributed to the 2022 EASL sclerosing cholangitis clinical practice guidelines (338 citations). Marlyn Mayo, MD, Professor of Internal Medicine at UT Southwestern, contributed to studies of alkaline phosphatase and bilirubin as disease progression markers and led a phase II trial of NGM282, an FGF19 analogue, in PSC (178 citations). Naga Chalasani, MD, Director of the Terence Kahn Liver Research Program at IU Health, first-authored the multicenter case-control study that quantified cholangiocarcinoma incidence in PSC patients (337 citations).

What PSC does to the liver and bile ducts

In PSC, chronic inflammation causes progressive fibrosis and stricturing of both the intrahepatic and extrahepatic bile ducts. Bile cannot drain normally, leading to cholestasis — bile acid accumulation in the liver that causes damage over time. Most patients have large-duct PSC visible on magnetic resonance cholangiopancreatography (MRCP) as a "beaded" pattern of multifocal strictures. A minority have small-duct PSC, which is not visible on imaging and is diagnosed only on liver biopsy; small-duct PSC generally carries a better prognosis.

The natural history is variable. Some patients remain stable for years; others progress within a decade to cirrhosis, portal hypertension, and liver failure. The AASLD guideline by Kalloo and colleagues documents that median time from diagnosis to death or transplantation is approximately 12–15 years in population-based studies, though this varies considerably.

The IBD connection: why most PSC patients have inflammatory bowel disease

Approximately 70% of patients with PSC have concomitant inflammatory bowel disease, most commonly ulcerative colitis. This association is so strong that any patient newly diagnosed with PSC should undergo colonoscopy if they have not already, and conversely, any IBD patient with unexplained elevated liver enzymes should be evaluated for PSC.

The IBD associated with PSC has distinctive features: it tends to be pancolitis with rectal sparing, relatively mild luminal symptoms despite extensive disease, and — critically — a significantly elevated risk of colorectal cancer compared to IBD patients without PSC. Current guidelines recommend annual colonoscopy with surveillance biopsies for PSC-IBD patients, not the standard 1–3 year IBD surveillance interval. Bowlus's 2022 AASLD practice guidance reinforces this recommendation given the disproportionate colorectal cancer risk in this population.

The underlying reason for the PSC-IBD association is not fully understood, but genome-wide association studies have identified immune-related genetic risk loci shared between PSC and IBD. Bowlus and collaborators identified nine new risk loci in a dense genotyping study, many overlapping with loci previously associated with Crohn's disease and ulcerative colitis, confirming that PSC is fundamentally an immune-mediated disease with a genetic architecture that partially resembles IBD.

Cholangiocarcinoma: the cancer risk that demands surveillance

PSC patients face a lifetime risk of cholangiocarcinoma (CCA) — bile duct cancer — estimated at 10–15%, compared to a rate of roughly 0.01% in the general population. This is the complication that most urgently shapes how PSC is managed.

Chalasani's multicenter case-control study of 26 PSC patients with CCA and 87 PSC controls found that CCA can develop at any stage of PSC disease severity, not only in advanced disease, underscoring the need for surveillance from the time of diagnosis. Most concerning, CCA can arise within the first year of PSC diagnosis, suggesting that some tumors are present but undetected at the time PSC is first identified.

Levy's research established the clinical role of serum CA 19-9 in CCA screening. Her study in Digestive Diseases and Sciences found that CA 19-9 values above 129 U/mL had a sensitivity of 79% and specificity of 98% for detecting CCA in PSC patients. The EASL guidelines Levy contributed to recommend annual MRCP plus serum CA 19-9 as the standard surveillance protocol, though neither test is perfectly sensitive. Dominant biliary strictures detected on imaging warrant biliary brush cytology and/or fluorescence in situ hybridization (FISH) to evaluate for malignancy.

Why no drugs have worked — and what is being tested

Ursodeoxycholic acid (UDCA) was the most studied medical therapy for PSC, but randomized trials showed that high-dose UDCA (28–30 mg/kg/day) actually increased the risk of adverse outcomes including CCA, and is not recommended. Lower doses do not appear harmful but provide no proven benefit.

Research has pivoted toward targeting the farnesoid X receptor (FXR), a bile acid nuclear receptor involved in bile acid homeostasis. Cilofexor, a nonsteroidal FXR agonist, was tested in a trial that Bowlus contributed to. The 2019 study in Hepatology found that cilofexor significantly improved markers of cholestasis — including alkaline phosphatase and alanine aminotransferase — compared to placebo in PSC patients. These results were hypothesis-generating rather than practice-changing, and phase III studies are needed.

Mayo's phase II trial of NGM282, an engineered analogue of the endocrine hormone FGF19, in PSC found that the drug impacted fibrosis turnover and hepatic inflammation markers, though it did not change alkaline phosphatase levels — highlighting the complexity of identifying appropriate endpoints for PSC trials and the ongoing challenge of developing therapies for this disease.

When liver transplant is indicated

Liver transplantation is the only treatment shown to extend survival in PSC patients with end-stage liver disease. PSC patients receive additional points in the MELD (Model for End-Stage Liver Disease) scoring system used to prioritize transplant allocation, recognizing that standard MELD may underestimate disease severity in some PSC cases.

Post-transplant outcomes are generally favorable — 5-year survival rates of approximately 80–85% — but PSC recurs in the allograft in 20–30% of patients over time. IBD may worsen after transplantation due to changes in immune modulation, and colorectal cancer surveillance must continue even after transplant.

Questions to ask your doctor

• How frequently should I have MRCP and CA 19-9 testing to screen for cholangiocarcinoma?
• Given that I have PSC, how often should I have colonoscopy surveillance for colorectal cancer — is the standard IBD schedule appropriate for me?
• What are my liver function trends over time, and what values would prompt consideration of transplant listing?
• Are there clinical trials of FXR agonists or other agents I might qualify for?
• If I have a dominant stricture on MRCP, what is the next step — biliary brushings, FISH, or ERCP?
• Should my children or siblings be screened for PSC?

The bottom line

PSC is a serious liver disease with no approved disease-modifying therapy and a meaningful lifetime risk of bile duct cancer. The priorities for any PSC patient are regular cholangiocarcinoma surveillance with MRCP and CA 19-9, vigilant colonoscopy for colorectal cancer if IBD is present, and monitoring liver function for progression toward transplant candidacy. Emerging FXR-targeted therapies offer the first realistic hope of slowing disease, but expert hepatology follow-up is essential in the meantime.